BIOTECH CATALYST AI SCANNER — April WK5

Conference season is at full speed. Between May 14 and June 2, the scan runs through SID, ISPOR, ATS, ISSVA, and ASCO in near-continuous succession — a stretch where abstracts drop before the prior week's data has been fully digested, and catalyst-driven small-caps often move on embargo lifts rather than the actual presentation. The XBI has stabilized after the late-March correction and is holding near its 50-day moving average, but institutional positioning in small-cap biotech remains measured. Macro noise around trade policy has kept risk appetite cautious, and rotation into large-cap defensives continues to be a headwind for sub-$100M names — several of which appear below.

The PDUFA pair from last week — MNKD on May 29 and CING on May 31 — returns, both with updated technicals. MNKD's BSI has compressed as the ML engine rebalances on a softer momentum print; the fundamental thesis is unchanged but the stock has given up some of its earlier overbought condition. RLAY remains the most structurally unusual entry in the scan: up 55.7% in three weeks, $2.83B market cap, $25M in cash, and its May 20 catalyst is a 20-patient initial dataset in vascular anomalies. The BTD and Phase 3 breast cancer setup are real — the ISSVA dataset is not the Phase 3.

BIVI enters the scan with a negative enterprise value — $12M market cap below its $14.7M cash balance — heading into Phase 2 Parkinson's conference data. Deep value with real catalyst optionality and a genuinely cautious scoring backdrop: the SUNRISE-PD design is small, decentralized, and tests monotherapy in a population where prior gains required levodopa adjunct. Four new names join the featured list: WVE (RNA editing, ATS May 18), FENC (Japan otoprotection, ASCO June 1), GLSI (HER2 vaccine, ASCO June 1), and CRVS (ITK inhibitor in AD, SID May 14).

What We're Tracking:

Trading Below Cash: BIVI
Cash Pressure: PSTV, RLAY, GLSI
Initial Data: BIVI, RLAY, ABCL (watchlist)
Multi-Catalyst: MRNA (watchlist, 2 catalysts at ASCO)

FEATURED — #1 through #10

#1. PSTV — PLUS THERAPEUTICS Inc.

THE CATALYST
Event: CNSide — Phase 1 Conference Presentation in Breast/NSCLC Leptomeningeal Metastases
Date: May 17, 2026
BSI: 7.91/10

Three payer agreements — UnitedHealthcare, Humana, and Highmark — now cover 75 million lives for CNSide, and the AMA issued a reimbursement billing code in April 2026, completing the commercial infrastructure weeks before ISPOR. Plus is a Houston-based company developing targeted radiotherapeutics (REYOBIQ, in Phase 1 for leptomeningeal disease) alongside the CNSide CSF liquid biopsy diagnostic. SpectronRx handles late-stage manufacturing supply for the radiotherapeutic program. A 1-for-25 reverse split in April 2026 restored Nasdaq compliance.

📈 The Setup: Standard-of-care CSF cytology (direct microscopic examination of cancer cells in cerebrospinal fluid) detects leptomeningeal metastases (LM; cancer that has spread to the membranes surrounding the brain and spinal cord) in only 29% of cases. CNSide quantifies circulating tumor cells and ctDNA (tumor-derived genetic fragments shed into spinal fluid) via molecular techniques, catching LM in 80% of cases where cytology came up empty, and influenced treatment decisions in 91% of FORESEE's 66 patients against a 20% threshold target. The ISPOR poster on May 17 presents the health economics case: a Harvard-co-authored cost-offset model projecting 40% savings in LM management costs through earlier detection. The payer infrastructure — 75 million covered lives, AMA billing code — is already in place. What hasn't followed is routine ordering by oncologists, and with 7 months of runway, that ramp needs to begin. This is a conference presentation, not a binary approval event. The outcome is either a stronger payer narrative or exposure of the model's cost assumptions.

✅ The Edge: CNSide holds the only prospective decision-impact dataset in LM diagnostics. No CSF ctDNA sequencing approach or lab-developed assay competitor has a published trial of comparable size or a validated clinical endpoint. The 75-million-life payer infrastructure is in place before most rivals have reached their first clinical enrollment.

⚠️ The Risk: Lab-developed test (LDT) status exposes CNSide to FDA's expanded 2024 oversight rules — a reimbursement fight analogous to Guardant360's early coverage battles with payer LCDs. Seven months of runway against zero revenue yet flowing from those 75 million covered lives is the defining structural constraint, not the science.

#2. WVE — Wave Life Sciences Ltd.

THE CATALYST
Event: WVE-006 — Phase 1/2 Interim Data in Alpha-1 Antitrypsin Deficiency
Date: May 18, 2026
BSI: 7.91/10

Wave regained full control of WVE-006 from GSK in February 2026 — removing the co-development constraints that had shaped the program's timeline — and followed that with positive obesity Phase 1 data in March. Wave is a Singapore-domiciled RNA-targeting company (proposing U.S. redomiciliation mid-2026) developing AIMers and siRNAs for genetics-driven disorders including AATD, obesity, DMD, and liver disease. A GSK supply agreement for atirmociclib and palbociclib remains active on separate combination studies.

📈 The Setup: Alpha-1 antitrypsin deficiency (AATD; an inherited disorder caused by a PiZ amino acid substitution in the SERPINA1 gene, causing the liver to produce misfolded Z-AAT protein instead of functional M-AAT, leading to progressive lung damage and liver cirrhosis in the 100,000 Americans with the severe homozygous PiZZ genotype) has no disease-modifying approved treatment. Weekly IV augmentation with plasma-derived AAT — from Grifols (Prolastin-C), CSL Behring (Zemaira), or Kamada (Glassia) — replaces protein without addressing the root mutation. The main rival in development, fazirsiran (Arrowhead/Takeda; an RNAi that knocks down all AAT production to halt liver damage), works by elimination. WVE-006 takes a different approach: it's a GalNAc-conjugated AIMer (RNA editing oligonucleotide delivered to liver cells via a GalNAc sugar tag that recruits the cell's own ADAR enzyme to correct the PiZ mutation back to functional PiM sequence). The allele-specific distinction matters — fazirsiran removes all AAT including residual Z-AAT, while WVE-006 converts it. Prior 200mg SAD data showed peak M-AAT of 7.2 μM (64% total AAT), but the 400mg SAD underperformed at 5.3 μM despite higher exposure — a dose-response puzzle that multidose accumulation might resolve. The ATS readout on 400mg and 600mg multidose data answers whether accumulation pushes M-AAT above the 11 μM threshold where durable lung protection becomes plausible. Open-label, 5–8 patients per cohort; this is not pivotal data — it's the inflection point for Phase 3 dose selection.

✅ The Edge: WVE-006 is the only clinical-stage program converting PiZ back to functional M-AAT rather than eliminating production. The $558M cash balance funds ATS, the obesity program readout, and a DMD NDA filing without requiring additional capital — a position that gives Wave flexibility to optimize the dose rather than rush to Phase 3.

⚠️ The Risk: The 400mg SAD underperforming the 200mg SAD at prior timepoints is a genuine signal, not noise — if multidose accumulation also fails to surpass the 200mg ceiling, the dose-response thesis doesn't hold. Cohorts of 5–8 patients are volatile; a single outlier shifts the group mean. FDA has no precedent for RNA editing accelerated approval on an M-AAT surrogate endpoint, which means the registrational path is genuinely undefined.

#3. MNKD — MannKind Corporation

THE CATALYST
Event: Afrezza (Technosphere Insulin) — PDUFA Regulatory Decision in Pediatric Type 1/2 Diabetes
Date: May 29, 2026
BSI: 7.90/10

FDA accepted the Afrezza pediatric sBLA despite INHALE-1 missing its prespecified HbA1c noninferiority margin — a judgment call in MannKind's favor that is itself a meaningful signal heading into May 29. MannKind is a Connecticut-based specialty pharma company anchored by the Afrezza inhaled insulin franchise, with adult revenues running above $100M annualized. The October 2025 scPharmaceuticals acquisition added FUROSCIX (subcutaneous furosemide for outpatient heart failure edema) as a second commercial asset; United Therapeutics pays royalties on Tyvaso DPI, which runs on the same Technosphere dry-powder delivery platform.

📈 The Setup: No inhaled insulin has ever been approved for children. NovoLog (insulin aspart) and Humalog (insulin lispro) are the injectable standards, cleared for ages 2+, and roughly 40% of pediatric type 1 patients report needle anxiety as an adherence barrier. Afrezza works through Technosphere microparticles (a dry powder formulation that dissolves in the lung lining within 12 minutes, producing a pharmacokinetic profile closer to normal mealtime insulin secretion than any injected analog) to deliver human insulin without injection. In INHALE-1 (N=230, ages 4–17), Afrezza achieved clinically comparable HbA1c (glycated hemoglobin, the standard three-month blood glucose measure) control at 26 weeks versus injected analogs, with stable FEV1 (forced expiratory volume, the primary lung function metric) throughout. The complication: the prespecified noninferiority margin was missed statistically — the HbA1c data was comparable but not formally noninferior by the trial's own threshold. FDA's sBLA acceptance despite that miss is a meaningful signal in MannKind's direction. A 52-week open-label extension showing mild HbA1c drift in the Afrezza arm will be in every reviewer's file on May 29. The adult REMS program and lung cancer monitoring warning don't disappear for a pediatric application.

✅ The Edge: First-mover exclusivity in pediatric inhaled insulin, with no generic competition possible for a device-drug combination. The adult commercial infrastructure — physician education, payer contracting, school nurse protocols — extends directly to a pediatric label without a rebuild.

⚠️ The Risk: Exubera's 2007 market withdrawal — the only prior inhaled insulin, pulled after lung cancer signals in adult smokers — still shapes FDA's pediatric pulmonary safety instinct. The open-label INHALE-1 design leaves the trial vulnerable to bias scrutiny, and the statistical noninferiority miss gives any reviewer a documented basis for a complete response letter if they're looking for one.

#4. CING — Cingulate Inc.

THE CATALYST
Event: CTx-1301 — PDUFA Regulatory Decision in Pediatric ADHD
Date: May 31, 2026
BSI: 7.75/10

CTx-1301's Phase 3 peak effect size of 1.19 at the 37.5mg dose sits above the typical stimulant class range of 0.8–1.0 — a clean efficacy signal heading into the May 31 PDUFA that the current $64M cap isn't reflecting. Cingulate is a Kansas City CNS company built around its Precision Timed-Release (PTR™) platform, which engineers multi-pulse drug delivery from a single tablet; CTx-1301 is its only near-term program. Bend Bio Sciences holds the exclusive manufacturing contract; a $12M PIPE closed in February 2026 and formulation patents extend to 2042.

📈 The Setup: Down 17.7% over the past three weeks with RSI at 36 — technically oversold heading into a PDUFA where the Phase 3 data is genuinely strong. CTx-1301 delivers dexmethylphenidate hydrochloride (a CNS stimulant that elevates dopamine and norepinephrine in prefrontal circuits) through three timed-release layers: immediate onset, a midday pulse at approximately 4 hours, and a sustained extension at approximately 8 hours that stretches coverage to 16 hours. Focalin XR peaks at 8–12 hours; Vyvanse's duration claims taper meaningfully in late afternoon. In the pediatric Phase 3 (NCT05286762; N=271, ages 6–17), CTx-1301 met its primary ADHD-RS-5 (ADHD Rating Scale-5, a validated 18-item symptom score) endpoint with p<0.001 at all doses, and the 37.5mg peak effect size of 1.19 sits at the top of the stimulant class range. The tension is commercial, not regulatory: the ADHD stimulant market is the most generic-saturated space in CNS psychiatry, with Focalin XR, Adderall XR, and Vyvanse all facing generic competition. Prescribers have limited incentive to pay brand premium for a novel formulation when cheap options cover the school day. The $64M cap is pricing commercial skepticism, not approval uncertainty.

✅ The Edge: If approved, CTx-1301 would be the only 16-hour once-daily stimulant with pediatric labeling — filling a late-afternoon coverage gap that contributes to homework-time behavioral issues that parents and teachers cite in clinical practice. FDA's willingness to engage on a novel tri-modal PK architecture without requesting additional bridging studies is itself an implicit signal of regulatory comfort.

⚠️ The Risk: Bend Bio Sciences' commercial-scale manufacturing is unproven beyond clinical lots, and FDA has a documented history of requesting pre-approval facility inspections that surface variability in novel formulation scale-ups. The generic stimulant wave has reduced physician urgency to try new options — even well-differentiated ones — absent a compelling coverage gap that patients can articulate to their prescriber.

#5. FENC — Fennec Pharmaceuticals Inc.

THE CATALYST
Event: STS-J01 — Phase 2/3 Conference Presentation in Pediatric Non-Metastatic Solid Tumors
Date: Jun 01, 2026
BSI: 7.73/10

STS-J01 pharmacokinetics confirmed that sodium thiosulfate co-administration does not reduce systemic cisplatin exposure — directly addressing the objection that has historically slowed otoprotectant adoption among oncologists who feared blunting chemotherapy efficacy. Fennec is a Canadian-domiciled specialty pharma company (Nasdaq-listed, North Carolina HQ) focused entirely on PEDMARK, the only approved otoprotectant for pediatric cisplatin patients; Norgine handles Europe, Australia, and New Zealand commercialization. Debt was cleared via equity offerings and Petrichor notes in 2025, and four PEDMARK abstracts are accepted at ASCO 2026 alongside STS-J01.

📈 The Setup: PEDMARK is already approved and sold in the U.S. and EU. This ASCO presentation is about Japan, where cisplatin-induced hearing loss — occurring in 56–63% of pediatric patients under observation-only standard — remains unaddressed. STS-J01 was an investigator-initiated single-arm Phase 2/3 trial (N=27 evaluable children ages 3–18 with neuroblastoma, hepatoblastoma, or germ cell tumors) comparing PEDMARK to historical controls. It hit its primary endpoint: 24% hearing loss incidence (ASHA grade ≥2) versus 56–63% historical, with 95% antitumor response rate preserved. The pharmacokinetic data confirmed that TAMP delivery (trans-arterial micro-perfusion; a catheter-based intra-arterial infusion method) reduced systemic gemcitabine exposure while preserving local concentrations — directly answering the longstanding objection about chemotherapy efficacy interference. Japan's PMDA historically prefers randomized trial data; a 27-patient single-arm study versus historical comparators is a meaningful gap on that standard. The ASCO June 1 presentation positions a Japan NDA conversation rather than triggering one. This is incremental data, not a binary catalyst.

✅ The Edge: PEDMARK has no approved rival anywhere in the world. The STS-J01 antitumor response preservation data — 95% response rate despite sodium thiosulfate co-dosing — directly answers the objection that historically slowed ototoxicity prevention adoption across the cisplatin-prescribing community. No other investigational otoprotectant has Phase 2/3 data in this population.

⚠️ The Risk: Single-arm, investigator-led, 27 evaluable patients versus historical comparators is not a PMDA-ready design — Japan's regulatory track record on historical control trials is more conservative than the FDA's, and a bridging RCT requirement could add years to the Japan NDA timeline. The cisplatin pediatric market in Japan is measured in hundreds of patients annually, meaning revenue even after successful registration is modest without broader label expansion.

#6. BIVI — BioVie Inc.

THE CATALYST
Event: Bezisterim (NE3107) — Phase 2 Conference Presentation in Parkinson's Disease
Date: May 17, 2026
BSI: 7.70/10

A $13.1M U.S. Department of Defense grant fully funds BioVie's Phase 2 ADDRESS-LC trial of bezisterim in long COVID neurological symptoms — non-dilutive support for one program independent of the operating cash balance. BioVie is a Nevada-based company developing bezisterim across neurological disorders (Parkinson's disease, Alzheimer's disease, long COVID) and advanced liver disease; bezisterim rights were acquired from NeurMedix in 2021. SUNRISE-PD enrollment of 60 early Parkinson's patients completed January 2026.

📈 The Setup: $12M market cap trading below its cash balance — maximum deep value compression heading into Phase 2 Parkinson's data. Bezisterim (NE3107) is an oral, blood-brain barrier-permeable small molecule that selectively binds ERK (extracellular signal-regulated kinase, an enzyme coordinating neuroinflammatory signaling and insulin resistance in the brain) to suppress the NFkB/TNF-α inflammatory cascade. The mechanism is entirely distinct from the dopamine-replacement standard (levodopa/carbidopa and MAO-B inhibitors like rasagiline) and from the alpha-synuclein targeting that Roche/Prothena pursued in prasinezumab before its Phase 2 mixed results. In the prior Phase 2a (N=63 moderate-severe PD patients on levodopa adjunct), the drug arm gained over 3 points more on MDS-UPDRS Part III (a standardized motor examination score where improvement is a decrease) than placebo, plus improved the NMSS sleep/fatigue domain by -2.4 points versus +1.0 worsening. SUNRISE-PD tests bezisterim as monotherapy in early untreated patients diagnosed within 4 years — a design that could either demonstrate cleaner disease-modifying signal, or simply miss, given that prior gains required levodopa co-treatment in late-stage disease. The May 17 conference presentation covers interim Phase 2 data, not topline. This is a signal check, not a definitive readout.

✅ The Edge: The DoD long COVID grant demonstrates independent scientific validation of the ERK mechanism from a non-biotech funder. Trading below cash means the SUNRISE-PD program is currently free-optioned — any signal from the interim data reprices it from zero.

⚠️ The Risk: Every disease-modification program showing adjunct gains in advanced PD has stumbled when retested as monotherapy in early disease — Roche/Prothena's prasinezumab being the most recent example. SUNRISE-PD is small (N=60) with decentralized home video motor assessments that introduce rater variability the centralized review is meant to control but may not fully resolve. The path to partnership in Parkinson's is narrow against better-capitalized Phase 3 programs from Roche and AbbVie.

#7. CRBP — Corbus Pharmaceuticals Holdings Inc.

THE CATALYST
Event: CRB-701 — Phase 1/2 Conference Presentation in Oncology
Date: May 29, 2026
BSI: 7.67/10

FDA aligned on April 7 on registrational study designs for both second-line HNSCC and cervical cancer — endorsing ORR vs. physician's choice chemo as the sole primary endpoint, an unusually concrete commitment at Phase 1/2 stage. Corbus is a Norwood, Massachusetts oncology company advancing CRB-701 (a Nectin-4 ADC licensed from CSPC Megalith Biopharma) and CRB-913 (an obesity program with Phase 2 topline expected summer 2026); CRB-601 was discontinued in March 2026 to concentrate resources. A $75M public offering in Q4 2025 funds the runway.

📈 The Setup: CRB-701 is a next-generation Nectin-4-targeted ADC (antibody-drug conjugate; an antibody linked to a cytotoxin via a cleavable linker that selectively releases inside tumor cells after binding the Nectin-4 surface protein). Nectin-4 (a cell adhesion molecule overexpressed in urothelial, head and neck, cervical, and other carcinomas) is the same target as PADCEV (enfortumab vedotin; Astellas/Pfizer), the approved standard in advanced urothelial cancer. CRB-701 differentiates via site-specific conjugation producing a homogeneous DAR4 (drug-to-antibody ratio, the number of cytotoxin molecules attached per antibody) and Fc modifications that recruit immune effectors beyond direct cytotoxic payload delivery. In Phase 1/2 dose expansion (N=122 evaluable), 3.6 mg/kg Q3W showed ORR of 47.6% in HNSCC (n=21), 37.5% in cervical cancer (n=16), and 55.6% in mUC (n=18) — well above the 10–15% ORR benchmark for second-line chemo. The ASCO May 29 presentation introduces durability data (duration of response) that the prior ESMO cutoff couldn't mature. Response rate without durability is an incomplete picture; that's the variable this conference resolves.

✅ The Edge: FDA's April 7 endorsement of ORR vs. chemo as the registrational bar is unusually concrete alignment for Phase 1/2-stage data — it removes endpoint negotiation risk and accelerates design finalization relative to ADC programs still in that conversation. PADCEV has no FDA-approved label in HNSCC; CRB-701 has a clear lane in that histology with superior confirmed ORR.

⚠️ The Risk: The ASCO dataset covers 122 evaluable patients across multiple tumor types from a data cut in September 2025 — confirmed ORR in the ASCO update could come in below the unconfirmed interim numbers, and durability figures exposing responses shorter than 4 months have previously stalled fast-tracked ADC programs at confirmatory filing.

#8. RLAY — Relay Therapeutics Inc.

THE CATALYST
Event: Zovegalisib + Fulvestrant + Ribociclib Triplet — Phase 3 Conference Presentation in PIK3CA-Mutant Breast Cancer / Initial Vascular Data
Date: May 20, 2026
FDA Status: BTD
BSI: 7.66/10

April 2026 triplet data showed 0% Grade 3+ hyperglycemia in 47% prediabetic patients — a concrete tolerability differentiator from alpelisib that anchors the frontline Phase 3 case. Two months of cash at a $2.83B cap is the financial context that defines every other fact about this entry. Relay is a Cambridge, Massachusetts computational drug discovery company deploying its Dynamo platform (machine learning and structural biology for conformationally flexible targets) in precision oncology; FDA Breakthrough Therapy Designation was granted in February 2026 and Pfizer supplies combination study materials under a separate agreement.

📈 The Setup: Zovegalisib (RLY-2608) is a pan-mutant-selective allosteric PI3Kα inhibitor (exploiting a conformation unique to mutant PI3Kα to suppress pathway activation while sparing the wild-type isoform). In PIK3CA-mutant HR+/HER2- metastatic breast cancer, the approved options — alpelisib (Piqray; with 25%+ metabolic discontinuations) and capivasertib (Truqap; for PIK3CA/AKT1/PTEN-low subsets) — both have tolerability constraints zovegalisib addresses. The ReDiscover Phase 1/2 doublet (N=57 post-CDK4/6 + endocrine) delivered 11.1-month median PFS and 43% ORR with 7% TRAE discontinuations; the triplet (adding atirmociclib, a CDK4/6 inhibitor) showed 44% ORR and zero Grade 3 hyperglycemia despite 47% baseline prediabetes. The ISSVA catalyst on May 20 covers preclinical and initial data in PIK3CA-driven vascular anomalies (rare developmental malformations caused by the same PI3Kα mutation pathway), approximately 20 patients. Vascular proof-of-concept expands the label opportunity, but the market is pricing the Phase 3 ReDiscover-2 breast cancer outcome, not the vascular dataset. The financing conversation at a $2.83B cap with 2 months of cash is happening regardless of May 20.

✅ The Edge: Zero Grade 3+ hyperglycemia in 47% prediabetic patients at the triplet dose is a specific, numerical differentiator from alpelisib — not a theoretical one. The BTD enables intensive FDA interaction before Phase 3 completion. ReDiscover-2's direct comparison to capivasertib + fulvestrant is the head-to-head that will define the commercial case.

⚠️ The Risk: Equity dilution is mathematically certain with 2 months of cash against a $2.83B cap — timing and size of the raise are the variables, not whether it happens. The ISSVA vascular dataset is roughly 20 patients; a disappointing readout resets sentiment in the weeks before ReDiscover-2 data that actually matters. Capivasertib's 7.2-month PFS bar in similar post-CDK4/6 lines is the benchmark ReDiscover-2 must clear.

#9. GLSI — Greenwich LifeSciences Inc.

THE CATALYST
Event: GP2 (GLSI-100) — Phase 3 Conference Presentation in HER2-Positive Breast Cancer
Date: Jun 01, 2026
FDA Status: FTD
BSI: 7.62/10

The DSMB's December 2025 recommendation to expand FLAMINGO-01 enrollment past the pre-specified interim doubled the addressable population beyond the 35% HLA-A02 subtype — driven by strong immune signals in the non-HLA-A02 open-label arm mirroring Phase 2b's >80% recurrence reduction. Greenwich LifeSciences is a single-asset company focused entirely on GP2 peptide immunotherapy for HER2-positive breast cancer, running FLAMINGO-01 across a multinational network including US Oncology, GEICAM, GIM, Unicancer, GBG, and City of Hope. FDA cleared commercial GP2 lots in January 2026; negative cash balance means financing is required before or shortly after ASCO.

📈 The Setup: GP2 is a peptide immunotherapy that combines a short HER2 transmembrane epitope (amino acids 654–662) with GM-CSF to prime CD8+ T-cells (cytotoxic immune cells that destroy tumor cells) against residual HER2-expressing cancer cells post-standard therapy. The mechanism is distinct from trastuzumab, which works via antibody-mediated HER2 signal blockade — GP2 trains the immune system to kill residual cells expressing the HER2 surface protein. Phase 2b (N=154 randomized, HER2 3+) showed >80% recurrence reduction over 5 years — substantially above the ExteNET benchmark for neratinib (an irreversible TKI that improved 5-year DFS from 87.7% to 90.2% in post-trastuzumab patients). FLAMINGO-01 is the Phase 3 confirmation. The ASCO June 1 presentation covers immune response data — elevated DTH (delayed-type hypersensitivity; the injection-site immune reaction that validates T-cell priming) at months 4 and 6 versus baseline in the first 40 patients. DTH confirms immune activation, not DFS outcomes directly. The DSMB didn't stop early for efficacy — it expanded enrollment, meaning the pre-specified interim threshold wasn't crossed in either direction.

✅ The Edge: The Phase 2b >80% recurrence reduction in HER2 3+ patients is the strongest recurrence prevention signal in post-trastuzumab HER2 breast cancer. The DSMB's expansion into the non-HLA-A*02 arm doubles the addressable population and reflects committee confidence in the immune signal. No rival Phase 3 peptide vaccine has reached this stage in HER2 breast cancer.

⚠️ The Risk: DSMB recommending expansion past interim is not a positive efficacy signal — the trial didn't meet its pre-specified interim bar. DTH at ASCO is immune activation data; its correlation with eventual DFS in this specific trial has not been validated. Negative cash and 3 months of runway means dilution arrives near or immediately after the ASCO presentation regardless of data quality.

#10. CRVS — Corvus Pharmaceuticals Inc.

THE CATALYST
Event: Soquelitinib (CPI-818) — Phase 1 Conference Presentation in Moderate-to-Severe Atopic Dermatitis
Date: May 14, 2026
BSI: 7.56/10

Cohort 4 data — 56-day treatment with a 30-day drug-free follow-up showing sustained EASI-75 response rates — is the remission signal being presented as a SID late-breaker on May 14. Corvus is a South San Francisco company developing soquelitinib, an ITK inhibitor, across two franchises: T-cell lymphoma (PTCL; Phase 3) and atopic dermatitis (Phase 2, N=200 launched Q1 2026). Angel Pharmaceuticals (49.7% Corvus equity) holds Greater China rights and runs a parallel AD trial. Goldman Sachs launched Buy coverage in April 2026; January 2026 equity offering extended cash to 6+ years of parallel development.

📈 The Setup: Dupixent (dupilumab; Sanofi/Regeneron) and JAK inhibitors Rinvoq (upadacitinib; AbbVie) and Cibinqo (abrocitinib; Pfizer) collectively represent $10B+ in annual revenue and define the atopic dermatitis standard of care. Soquelitinib targets ITK (interleukin-2-inducible T-cell kinase, an enzyme that orchestrates pathogenic Th2 and Th17 immune responses in skin inflammation) to shift immunity toward Th1/Treg dominance without the broad cytokine suppression underlying JAK inhibitors' black-box cardiovascular and malignancy warnings. Placebo-controlled Phase 1 Cohort 3 (200 mg BID, 28 days, n=16 active) showed 71% mean EASI (Eczema Area and Severity Index, the standard AD severity score) reduction versus 42% placebo, with separation from day 8. Cohort 4 extended that to 56 days: EASI-75 (a 75% score improvement, an established regulatory benchmark) of 75% versus 20%, IGA 0/1 (cleared or almost clear skin on investigator global assessment) of 33% versus 0%, with responses holding post-treatment. The SID late-breaker on May 14 adds Cohort 4's 30-day drug-free follow-up — the remission signal that distinguishes ITK from continuous-dosing JAK inhibitors. Small-N Phase 1 data (12–16 active per cohort); the real read-through is for Phase 2 enrollment. The stock currently trades at an oncology multiple with the AD program largely unpriced.

✅ The Edge: Cohort 4's post-treatment response durability has no precedent among approved AD oral agents — JAK inhibitors require continuous dosing and Dupixent requires biweekly injections indefinitely. If Phase 2 confirms sustained responses after stopping drug, soquelitinib writes its own differentiation argument against the entire existing landscape.

⚠️ The Risk: FDA has never approved an ITK inhibitor in any indication, meaning the regulatory pathway for soquelitinib in AD is undefined — the agency will likely require Phase 2b superiority data before considering a filing in a therapeutic area with multiple approved alternatives. Phase 2's primary endpoint of EASI % change may not be sufficient; payers will want IGA 0/1 response rates and durability data that Phase 2 isn't powered to deliver at statistical significance.

WATCHLIST — #11 through #20

#11. DTIL — Precision BioSciences Inc. [Infectious Disease]

Price: $7.04 | Cap: $182M | Cash: $101M | RSI: 59.3 | Momentum: +16.9%
PBGENE-HBV — Phase 1/2 Conference Presentation in Chronic Hepatitis B (May 27, 2026)
FTD
BSI: 7.53/10

The Intel: PBGENE-HBV uses ARCUS nuclease (a compact gene editor targeting cccDNA — the persistent viral reservoir that allows hepatitis B to survive indefinitely despite antivirals like tenofovir and entecavir) to attempt functional cure in chronic HBV, a market where Gilead dominates treatment but no approved therapy eliminates the virus. Phase 1 highest dose cohort (0.8 mg/kg) showed steep HBsAg (hepatitis B surface antigen, the key viral marker) decline at day 14 with cumulative reductions after the second dose — mechanistically meaningful, though patient numbers are small. EASL May 27 presents expanded ELIMINATE-B data; rivals Vir Biotechnology (VIR-2218 siRNA) and Assembly Biosciences (capsid inhibitors) are competing but have not demonstrated cccDNA clearance. Functional cure endpoint pathway remains undefined with FDA.

#12. EDSA — Edesa Biotech Inc. [Pulmonary]

Price: $11.17 | Cap: $93M | Cash: $9M | RSI: 76.3 | Momentum: +91.9%
Paridiprubart — Phase 3 Conference Presentation in COVID-19 / ARDS (May 20, 2026)
FTD
BSI: 7.53/10

The Intel: Up 91.9% in three weeks with RSI 76 — EDSA is running hot into ATS, where it presents full data from the only positive Phase 3 trial in ARDS (acute respiratory distress syndrome; severe lung failure from hyperinflammation that kills roughly 75,000 Americans annually and has resisted every prior pharmacological attempt). Paridiprubart is a C5a receptor inhibitor (blocks a complement protein that triggers cytokine storm in lung injury) that cut 28-day mortality from 33% to 24% in 278 patients. With $9M cash and 13 months of runway, the financing timeline is tight regardless of ATS reception. The ARDS regulatory pathway is genuinely novel — no approved pharmacological treatment exists — which means FDA will set the evidentiary bar without prior precedent to follow.

#13. AGEN — Agenus Inc. [Oncology]

Price: $4.09 | Cap: $157M | Cash: $76M | RSI: 50.4 | Momentum: +20.6%
Botensilimab ± Balstilimab — Phase 2 Conference Presentation in Advanced Cutaneous Melanoma (May 31, 2026)
BSI: 7.50/10

The Intel: Botensilimab (BOT; a next-generation CTLA-4 inhibitor with enhanced FcγR engagement that activates effector T-cells and depletes immunosuppressive regulatory T-cells) combined with balstilimab (BAL; a PD-1 inhibitor) generated 52% ORR in frontline cutaneous melanoma — above ipilimumab + nivolumab's ~40% ORR benchmark. ASCO May 31 matures that response: durability and subgroup performance in PD-L1-negative patients are what the market needs to see beyond the early ORR figure. Opdivo/Yervoy is entrenched with mature 5-year survival curves, and Agenus needs a durability advantage, not just a response rate edge, to shift prescribing patterns. Open-label Phase 2 limits the conclusions by design.

#14. ABCL — AbCellera Biologics Inc. [Women's Health]

Price: $4.16 | Cap: $1.23B | Cash: $591M | RSI: 86.4 | Momentum: +27.2%
ABCL635 — Phase 1/2 Topline Data in Vasomotor Symptoms / Menopause (May 11, 2026)
BSI: 7.24/10

The Intel: ABCL635 is a long-half-life monoclonal antibody targeting NK3R (neurokinin-3 receptor, activated by neurokinin B to trigger vasomotor symptoms in menopausal women) designed for monthly subcutaneous dosing — competing against fezolinetant (Veozah; Astellas), the approved NK3R antagonist taken daily as an oral pill. RSI 86, 27% momentum, and a First Human Data flag reflect genuine early enthusiasm. But this is truly first-in-human data: no clinical evidence of hot flash reduction yet exists. The May 11 topline covers safety, PK, and early efficacy signals in approximately 20–30 patients — informative for program direction, not sufficient to draw efficacy conclusions. Approach with the skepticism appropriate for an inaugural Phase 1 readout.

#15. RNXT — RenovoRx Inc. [Oncology]

Price: $0.87 | Cap: $39M | Cash: $13M | RSI: 45.4 | Momentum: -23.0%
RenovoGem — Phase 3 Conference Presentation in Locally Advanced Pancreatic Cancer (May 21, 2026)
BSI: 7.19/10

The Intel: RenovoGem delivers gemcitabine (standard chemotherapy for pancreatic cancer) via TAMP (trans-arterial micro-perfusion; a catheter-based intra-arterial infusion system delivering drug at 8x higher local concentration in the pancreatic artery versus IV administration) for locally advanced pancreatic cancer, where FOLFIRINOX and gemcitabine/nab-paclitaxel are the current treatment backbones. ASCO GI January data confirmed reduced systemic exposure alongside elevated local levels — the pharmacological concept is working. The ASCO May 21 abstract covers Phase 3 enrollment status (>100 randomized, completion expected H1 2026) rather than efficacy data. This is a trial progress update, not a pivotal readout. Down 23% in three weeks; no near-term binary event to trade.

#16. ARGX — argenx SE [Neurology]

Price: $783.74 | Cap: $48.6B | Cash: $3.49B | RSI: 55.0 | Momentum: +13.4%
VYVGART (efgartigimod) — PDUFA Regulatory Decision in Myasthenia Gravis (May 10, 2026)
BSI: 6.97/10

The Intel: VYVGART is an FcRn inhibitor (blocks the neonatal Fc receptor to rapidly clear disease-causing IgG autoantibodies from circulation) already approved for generalized myasthenia gravis (gMG; an autoimmune disorder where antibodies attack nerve-muscle junctions, causing progressive muscle weakness). The ADAPT SERON PDUFA on May 10 covers a label or formulation extension — the subcutaneous Hytrulo version was approved in 2023. At $48.6B cap and $3.5B cash, argenx is large-cap infrastructure: a meaningful PDUFA for a company this size, tracked for platform read-through rather than as a volatility trade.

#17. ALXO — ALX Oncology Holdings Inc. [Oncology]

Price: $1.59 | Cap: $214M | Cash: $170M | RSI: 37.0 | Momentum: -22.1%
Zanidatamab + Evorpacept — Phase 1/2 Conference Presentation in HER2+ Breast Cancer (May 07, 2026)
BSI: 6.96/10

The Intel: Evorpacept (ALX148; a CD47 blocker that removes the "don't eat me" signal on tumor cells, enabling macrophage phagocytosis) combined with zanidatamab (a bispecific antibody binding two HER2 epitopes simultaneously) generated responses in HER2+ breast cancer, but Phase 1b/2 data in January 2026 showed responses largely restricted to patients with higher CD47 expression — a biomarker stratification that immediately narrows the commercial case before Phase 2 planning. Down 22% in three weeks, RSI 37. T-DXd (trastuzumab deruxtecan; AstraZeneca/Daiichi) dominates heavily pretreated HER2+ breast cancer. This ESMO Breast presentation is a biomarker-sorting dataset rather than a pivotal efficacy signal.

#18. CRDF — Cardiff Oncology Inc. [Oncology]

Price: $1.72 | Cap: $118M | Cash: $50M | RSI: 60.3 | Momentum: +11.0%
Onvansertib + Bevacizumab — Phase 2 Conference Presentation in Metastatic Colorectal Cancer (Jun 02, 2026)
BSI: 6.92/10

The Intel: Onvansertib is a PLK1 inhibitor (blocks polo-like kinase 1, a cell division regulator overactive in RAS-mutated tumors) combined with bevacizumab (anti-VEGF antibody starving tumor vasculature) in RAS-mutated metastatic colorectal cancer — tumors with KRAS/NRAS mutations that block response to EGFR inhibitors and represent roughly 50% of mCRC. January 2026 Phase 2 update showed 72.2% ORR at 30mg versus 43% SOC, dose-dependent, in bevacizumab-failed patients. The ASCO June 2 final data presentation includes mature PFS. RAS-mutant mCRC has seen many promising Phase 2 ORR signals fail to translate to Phase 3 OS benefit; durability and PFS endpoints at ASCO are the variables that separate this from prior false positives.

#19. IRON — Disc Medicine Inc. [Hematology]

Price: $68.85 | Cap: $2.63B | Cash: $734M | RSI: 56.5 | Momentum: +14.6%
DISC-0974 — Full Results Presentation in Myelofibrosis with Anemia (Jun 02, 2026)
BSI: 6.91/10

The Intel: DISC-0974 is a matriptase-2 inhibitor (blocks an enzyme that suppresses hepcidin — the iron-regulating hormone — allowing ineffective red blood cell precursors in myelofibrosis to deplete iron and sustain anemia) that increased hemoglobin by ≥1.5 g/dL for ≥12 weeks in 50% of baseline transfusion-dependent RALLY-MF patients per ASH December 2025 data. JAK inhibitors pacritinib and momelotinib address spleen and symptoms in myelofibrosis but anemia management remains a gap. The ASCO full results on June 2 will mature the dataset. Luspatercept (Reblozyl; BMS) received MF-related anemia approval in 2024, making DISC-0974 the second entrant, not a first-mover. At $2.63B cap and $734M cash, the catalyst is incremental rather than pivotal.

#20. MRNA — Moderna Inc. [Oncology]

Price: $48.70 | Cap: $19.3B | Cash: $7.18B | RSI: 46.1 | Momentum: -1.7%
Intismeran Autogene + Pembrolizumab — Phase 1 Conference Presentation in Resected Melanoma (Jun 01, 2026)
Additional catalysts: mRNA-2808 Phase 1/2 in Relapsed/Refractory Multiple Myeloma (Jun 01, 2026)
BSI: 6.91/10

The Intel: Intismeran is a personalized mRNA cancer vaccine (custom-synthesized mRNA encoding each patient's unique tumor neoantigens — mutation-derived protein fragments that mark cancer cells as foreign to the immune system) given with pembrolizumab (PD-1 checkpoint inhibitor). KEYNOTE-942 Phase 2b showed 44% reduction in recurrence risk in resected melanoma versus pembrolizumab alone, enabling Phase 3 enrollment now underway. The ASCO June 1 presentation is Phase 1 contextual data; the Phase 2b efficacy signal is already published. Moderna's mRNA-2808 (mRNA-based therapy for relapsed/refractory multiple myeloma) also presents at ASCO June 1. At $19.3B cap, this is a platform read-through watch, not a near-term catalyst trade.

The Strategist's Take

Conference season is doing what it always does — compressing timelines and forcing position decisions before data arrives. This week's scan runs from SID on May 14 through ASCO June 1–2, with ISPOR, ATS, and ISSVA layered in between. Several of these abstracts drop while readers are still processing the prior week's data.

The most structurally unusual entry on the list is RLAY. The Phase 3 breast cancer thesis — zovegalisib with Breakthrough Therapy Designation, head-to-head against capivasertib, 0% Grade 3 hyperglycemia in prediabetic patients — is legitimately interesting. But the May 20 ISSVA catalyst is not the Phase 3. It's a 20-patient initial dataset in PIK3CA-driven vascular anomalies, and the company has $25M in cash against a $2.83B market cap. Dilution is mathematically certain before Phase 3 data reads. WVE is the counterpoint: the RNA editing story on WVE-006 is scientifically differentiated and the ATS multidose data is the genuine inflection point for program direction — but Wave has $558M in cash and can afford to optimize the dose rather than rush. Those two setups reflect opposite ends of the Fortress-Pressure Cooker spectrum, and they're catalysting within 48 hours of each other in mid-May.

BIVI at $12M market cap trading below cash is the cleanest "being paid to wait" setup in the scan. The scoring signals are appropriately cautious — the SUNRISE-PD design is small and decentralized, the competitive landscape in Parkinson's disease modification is crowded with Roche and AbbVie running better-capitalized programs, and the catalyst quality is low given this is interim conference data rather than topline. But the valuation prices zero probability, and a marginal UPDRS signal reprices that from scratch. BIVI and GLSI share a structural characteristic worth noting: both are conference presentations where the company has near-zero operating runway. Neither needs a breakthrough — they need the data to be good enough to support a financing conversation at better terms.

The scored range this week is tighter than prior scans — BSI 7.56 to 7.91 across the featured list, with no outlier like MNKD's 8.55 from WK4. That compression reflects a mix of genuine second-tier conference catalysts and well-funded fortress names where the technical setup isn't as clean. Read the Risk sections on the lower-scored featured entries; they're substantive for a reason.

About This Scanner

This weekly report identifies biotech catalyst opportunities using quantitative screening combined with fundamental analysis.

What the Score Means: The BSI Score (0-10) reflects overall opportunity quality based on technical setup and fundamental characteristics. Higher scores indicate more favorable setups; lower scores indicate elevated uncertainty. This is NOT a prediction of catalyst outcomes or stock direction.

Data Sources: Financial data from market feeds and regulatory filings. Catalyst dates are estimates based on company guidance and subject to change.

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.

Scanner Version: 3.2 | Generated: 2026-04-28T08:55:15.606009